National Cancer Center

CSCO Foundation, Ping An Health Insurance and OrigiMed Announced Strategic Partnership for Innovative Ecosystem of Precision Medicine

Retrieved on:

Wednesday, May 17, 2023

PAH, Insurance, Ping An Insurance, Cancer, Research, Multimedia, National Cancer Center, Patient, Medicine, CSCO, Diagnosis, Death, Pharmaceutical industry

Cancer has emerged as a leading cause of death in China, with a growing burden of cancer patients in recent years.

Key Points:

Cancer has emerged as a leading cause of death in China, with a growing burden of cancer patients in recent years.
Under the terms of the agreement, the three parties will jointly develop an innovative ecosystem of precision medicine to provide full-cycle medical service for insured Chinese patients.
"Patients in China deserve the high-quality medical service that enable them to make informed decisions about personalized precision medicine."
"OrigiMed precision medicine e-hospital will serve as a core point connecting insured patients, doctors and healthcare institutions."

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

Retrieved on:

Tuesday, May 16, 2023

Under the agreement, National Cancer Center Hospital East (NCCHE) will recruit patients and conduct the clinical trial, Ono will provide nivolumab, and Personalis will perform MRD and biomarker testing.

Key Points:

Under the agreement, National Cancer Center Hospital East (NCCHE) will recruit patients and conduct the clinical trial, Ono will provide nivolumab, and Personalis will perform MRD and biomarker testing.
Biomarker research will be conducted throughout the study, including sample analysis from both tumor lesion tissue and plasma circulating tumor DNA (ctDNA).
Tissue samples will be analyzed by the Personalis ImmunoID NeXT ® platform to capture tumor molecular profile and tumor microenvironment features to better understand immunotherapy responses.
These comprehensive assays may enable the selection of cases with high efficacies and will promote the non-operative management in dMMR rectal cancer.”

Fujitsu conducts project with Takeda and National Cancer Center Japan to analyze and visualize of patient journey with ovarian cancer

Retrieved on:

Friday, May 12, 2023

These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.

Key Points:

These treatment patterns are expected to assist physicians and patients in jointly selecting optimal treatment.
This study was conducted based on a joint research agreement that Fujitsu concluded with Takeda and the National Cancer Center Japan in May 2021 with the aim of identifying clinical challenges that will contribute to improving the quality and therapeutic efficacy of personalized ovarian cancer treatment.
In the future, the platform will be able to extract patient medical data and convert it into HL7 FHIR(2).
It includes electronic medical record data, medical accounting data, health checkup data, patient registry data, and data obtained from wearable devices.

THIRA ROBOTICS' SECOND-GENERATION AMR CREATES DEMAND IN U.S. MARKET AHEAD OF AUTOMATE EXHIBIT

Retrieved on:

Wednesday, May 3, 2023

Exhibition, AWG, Samsung, AMR, Santorini, National Cancer Center, Hospital, Transport, Robotics, Warehouse

SEOUL, South Korea, May 3, 2023 /PRNewswire/ -- THIRA ROBOTICS - an S. Korean autonomous mobile robots developer and a subsidiary of THiRA UTech announced their upcoming AUTOMATE exhibition with the goal of providing optimized AMR units for employees in complex facilities. THIRA ROBOTICS (TR) officially launched in the U.S. in March to overcome obstacles of current AMR and will be deploying units in HYUNDAI TRANSYS' Alabama-based automotive parts factory. Live demonstrations will be held at AUTOMATE in Detroit from May 22 - 25.

Key Points:

SEOUL, South Korea, May 3, 2023 /PRNewswire/ -- THIRA ROBOTICS - an S. Korean autonomous mobile robots developer and a subsidiary of THiRA UTech announced their upcoming AUTOMATE exhibition with the goal of providing optimized AMR units for employees in complex facilities.
THIRA ROBOTICS (TR) officially launched in the U.S. in March to overcome obstacles of current AMR and will be deploying units in HYUNDAI TRANSYS ' Alabama-based automotive parts factory.
Live demonstrations will be held at AUTOMATE in Detroit from May 22 - 25.
Businesses seeking to learn more should visit booth #2450 at AUTOMATE for live demonstrations.

Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System

Retrieved on:

Monday, April 3, 2023

Insurance, Clinical trial, Cancer, National Cancer Institute, AYA, Government, Eisai, Histone, National Cancer Center, Patient, Standard of care, Health, Growth, Safety, EZH2, Adolescence, Pharmaceutical industry, Ipsen

TOKYO, Apr 3, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system.

Key Points:

TOKYO, Apr 3, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system.
This clinical research will be conducted by the National Cancer Center Hospital.
Researched and developed by Eisai and Epizyme, Inc.,** an Ipsen (Headquarters: France) company, tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2.
Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer.

ARS®/Rescue Rooter® donates more than $1.3 million to St. Jude Children's Research Hospital®

Retrieved on:

Friday, April 14, 2023

Insurance, St. Jude Children's Research Hospital, Partnership, Travel, Housing, Food, ARS, NCI-designated Cancer Center, ALSAC, Cancer, National Cancer Center, Organization, National Cancer Institute, Air conditioning, American Residential Services, Heat, Hospital, Nursing, Jude the Apostle

MEMPHIS, Tenn., April 14, 2023 /PRNewswire/ -- ARS/Rescue Rooter, a privately held Memphis-based company and the nation's largest provider of air conditioning, heating, and plumbing services, presented a $1.3 million check to ALSAC, the fundraising and awareness organization for St. Jude Children's Research Hospital®, following a year-long fundraising initiative across its more than 75 branches.

Key Points:

"At ARS, we believe in making a positive impact in the communities we serve, and one way to do that is by supporting St. Jude Children's Research Hospital," said Scott Boose, CEO, ARS/Rescue Rooter.
"We're honored to have raised over $6.7 million for this amazing organization, and we're committed to continuing our partnership with St. Jude to help children survive and thrive."
This support also helps ensure that St. Jude can continue to treat kids worldwide, including kids in communities across the ARS network.
Join ARS here in supporting the mission of St. Jude Children's Research Hospital.

THIRA ROBOTICS LAUNCHES NEXT-GENERATION AUTONOMOUS MOBILE ROBOTS (AMR) FOR TOUGH FACILITY CONDITIONS NOT PREVIOUSLY FIT FOR AUTOMATION

Retrieved on:

Monday, March 13, 2023

AMR, Santorini, National Cancer Center, Professional corporation, Plant, Automation, Promate

SEOUL, South Korea, March 13, 2023 /PRNewswire/ -- THIRA ROBOTICS — a Korean autonomous mobile robots (AMR) developer and a subsidiary of smart factory solutions leader THiRA UTech –– announced their official launch in the U.S. market, providing AMR to navigate facility conditions previously not fit for automation. THIRA ROBOTICS offers solutions to healthcare, manufacturing, and supply chain industries to overcome physical barriers to technology adoption. Their launch coincides with Promat 2023, held in Chicago starting March 20th.

Key Points:

SEOUL, South Korea, March 13, 2023 /PRNewswire/ -- THIRA ROBOTICS — a Korean autonomous mobile robots (AMR) developer and a subsidiary of smart factory solutions leader THiRA UTech –– announced their official launch in the U.S. market, providing AMR to navigate facility conditions previously not fit for automation.
THIRA ROBOTICS offers solutions to healthcare, manufacturing, and supply chain industries to overcome physical barriers to technology adoption.
With THIRA ROBOTICS, robotization is possible for facilities not fit for automation," says Peter Kim, CEO of THIRA ROBOTICS.
For those interested in customizable automated solutions, visit THIRA ROBOTICS' in-person demonstrations at Promat, booth #N6054.

Schwarzman Animal Medical Center Appoints Helen Irving, RN, MBA, President and Chief Executive Officer

Retrieved on:

Wednesday, January 25, 2023

Fairleigh Dickinson University, National Cancer Center, United Kingdom, Health, MBA, Health administration, AMC, Hospital, RN, NewYork-Presbyterian Hospital, Pet, NYIT, Stephen, Organization, Mount Sinai Medical Center, Family, Trustee, Nursing, Tobacco

NEW YORK, Jan. 25, 2023 /PRNewswire/ -- The Stephen & Christine Schwarzman Animal Medical Center Board of Trustees has announced Helen Irving, RN, MBA, as its incoming President and Chief Executive Officer. Ms. Irving joins AMC, the largest non-profit animal hospital in the world, on January 30, 2023, during a pivotal time for the 113-year-old Upper East Side institution. The hospital is currently undergoing a $100 Million expansion and modernization project to accommodate unprecedented demand for its veterinary care.

Key Points:

The Seasoned Healthcare Executive Brings 30+ Years of Clinical, Administrative, and Operations Experience
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- The Stephen & Christine Schwarzman Animal Medical Center Board of Trustees has announced Helen Irving, RN, MBA, as its incoming President and Chief Executive Officer.
The hospital is currently undergoing a $100 Million expansion and modernization project to accommodate unprecedented demand for its veterinary care.
An accomplished leader and healthcare executive, Helen Irving has devoted her 30-year career to operational excellence in the delivery of healthcare services.
"Leading the Schwarzman Animal Medical Center is such an exciting opportunity given my deep roots in New York's healthcare system," said Ms. Irving.

Chinese Medical Journal Article Reveals Gender-Based Differences in Lung Cancer Risk Among Non-Smokers

Retrieved on:

Thursday, January 12, 2023

So, a team of researchers from China published a multicenter, population-based cancer screening study under the China National Lung Cancer Screening (NLCS) Program, in the Chinese Medical Journal on June 5, 2022.

Key Points:

So, a team of researchers from China published a multicenter, population-based cancer screening study under the China National Lung Cancer Screening (NLCS) Program, in the Chinese Medical Journal on June 5, 2022.
After an average follow-up period of 4.8 years, 3,351 participants from the cohort were diagnosed with lung cancer.
Interestingly, they observed that males displayed a higher risk of developing lung cancer than their female counterparts.
Title of original paper: Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program

Precision Medicine Asia and National Cancer Center Hospital East Announce the Initiation of the LC-SCRUM-AP Genomic Screening Platform for the Asia-Pacific Region

Retrieved on:

Wednesday, December 21, 2022

TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.

Key Points:

TOKYO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Asia Co., Ltd. (“PREMIA”) and National Cancer Center Hospital East (“NCCHE”) announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific (LC-SCRUM-AP), a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.
LC-SCRUM-AP is a genomic screening platform for patients with advanced or recurrent non-small cell lung cancer.
The aim is to further develop precision medicine in Asia by establishing a genomic screening infrastructure for the Asia-Pacific region.
The integration of the LC-SCRUM-Asia and LC-SCRUM-AP databases will create an international, large-scale lung cancer clinicopathological database and contribute to the development of precision medicine in Asia.